Print Page | Close Window

New Clinical Trial/Research: PARP1 & Trip-Neg

Printed From: TNBC Foundation
Category: TNBC Forums
Forum Name: TNBC NEWS, RESOURCES and TIPS
Forum Description: Please look here for the latest articles, tips and resources.
URL: http://forum.tnbcfoundation.org/forum_posts.asp?TID=333
Printed Date: Mar 19 2019 at 11:56pm
Software Version: Web Wiz Forums 12.01 - http://www.webwizforums.com


Topic: New Clinical Trial/Research: PARP1 & Trip-Neg
Posted By: Joan2844
Subject: New Clinical Trial/Research: PARP1 & Trip-Neg
Date Posted: Oct 23 2007 at 10:46am

Hopefully this information can help some:

 

http://robperkin.blogspot.com/2007/10/bipar-announces-upcoming-data.html - BiPar Announces Upcoming Data Presentations Demonstrating Progress on PARP Inhibitor Drug Pipeline for Cancer

BRISBANE, Calif., Oct. 22 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that key data supporting its PARP (poly-ADP-ribose polymerase) inhibitor drug development programs will be presented at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics in San Francisco from Oct. 22 to 26 and the EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer" in Brussels, Nov. 15 to 17.

PARP is a novel, validated target for cancer treatment. PARP1 plays a central role in cell proliferation and in DNA repair. BiPar scientists will present results showing that PARP1 gene expression is significantly upregulated in many but not all tumor types. BiPar's novel, proprietary PARP inhibitors are members of a new generation of drug candidates that show promising activity and a favorable toxicity profile. Preclinical studies suggest the drugs selectively inhibit tumor cell proliferation and are active against a broad range of tumor types. BiPar is initiating Phase 1b and Phase 2 clinical trials of BSI-201, its lead PARP inhibitor, in several major cancers. That research program has been directed in large part by the molecular biomarker data being presented at these meetings.

"These findings will focus our efforts on those tumor types with the greatest opportunity for clinical success," said Barry Sherman, M.D., BiPar's executive vice president. "With this information we believe we will be able to efficiently exploit our pipeline of PARP inhibitors that target major unmet needs in cancer."

The schedule of presentations is as follows: Title: The novel PARP-1 inhibitor, BSI-401, has antitumor activity and potentiates oxaliplatin cytotopic activity in human pancreatic cancer When: Wednesday, Oct. 24, 2007, 12:30 p.m. PDT Where: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Moscone West Convention Center, San Francisco Presenter: Davide Melisi, M.D., Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center Title: PARP-1 gene over-expression in primary human cancers: A potential marker for PARP inhibition. When: Thursday, Oct. 25, 2007, 12:30 p.m. PDT Where: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Moscone West Convention Center, San Francisco Presenter: Valeria Ossovskaya, Ph.D. Director of Preclinical Development, BiPar Title: The PARP1 gene is over-expressed in triple negative breast cancer When: Thursday, Nov. 15, 6 to 8 p.m. CEST Where: EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer," Sheraton Brussels, Hotel & Towers, Brussels, Belgium Presenter: Valeria Ossovskaya, Ph.D. Director of Preclinical Development, BiPar About BiPar Sciences

BiPar Sciences Inc. (http://www.biparsciences.com/) is a clinical-stage biopharmaceutical company developing and commercializing a pipeline of novel, tumor-selective drugs designed to meet the significant unmet needs of cancer patients.

BiPar Sciences, Inc.

CONTACT: Eric Malek, Vice President of Corporate Development of BiPar
Sciences, 1-650-635-0165, emalek@biparsciences.com; or Brian Reid of
WeissComm Partners, 1-703-402-3626, breid@weisscommpartners.com for BiPar
Sciences

Web site: http://www.biparsciences.com/

 



-------------
9/06 Stage2B. Pos Nodes; Neg BRAC; TAC/Lumpectomy/Rads/Xeloda.
4/08 Local Recurrence; Mast w/ Latissimus Flap;Taxol/Gemzar/Carbo. Zometa.

NED since May 2008 :-)
www.wow-matt14.blogspot.com



Print Page | Close Window

Forum Software by Web Wiz Forums® version 12.01 - http://www.webwizforums.com
Copyright ©2001-2018 Web Wiz Ltd. - https://www.webwiz.net